Financials in USD. Standardized financial statements.
A compact view of how Towa Pharmaceutical Co., Ltd. turns revenue into operating income and net income.
| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $275.43B | $259.59B | $227.93B | $208.86B | $165.62B | $154.90B | $110.38B | $105.10B | $93.43B | $84.95B |
| Revenue Growth? | +6.1% | +13.9% | +9.1% | +26.1% | +6.9% | +40.3% | +5.0% | +12.5% | +10.0% | 0.0% |
| Cost of Revenue? | $175.71B | $164.87B | $146.55B | $136.15B | $95.43B | $89.45B | $59.74B | $56.70B | $50.38B | $45.90B |
| Gross Profit? | $99.73B | $94.73B | $81.38B | $72.71B | $70.19B | $65.45B | $50.65B | $48.40B | $43.05B | $39.05B |
| Gross Margin? | +36.2% | +36.5% | +35.7% | +34.8% | +42.4% | +42.3% | +45.9% | +46.0% | +46.1% | +46.0% |
| Operating Expenses? | $76.48B | $71.49B | $63.74B | $67.20B | $50.98B | $45.53B | $34.50B | $32.43B | $31.41B | $32.18B |
| Operating Income? | $23.25B | $23.24B | $17.65B | $5.51B | $19.20B | $19.92B | $16.14B | $15.97B | $11.64B | $6.87B |
| EBITDA? | $46.23B | $48.06B | $43.29B | $24.92B | $29.49B | $30.35B | $24.46B | $27.32B | $19.82B | $15.12B |
| Income Before Tax | $13.25B | $26.33B | $24.46B | $4.61B | $22.25B | $18.73B | $20.71B | $18.89B | $9.83B | $7.24B |
| Income Tax Expense | $7.96B | $7.34B | $8.29B | $2.40B | $6.33B | $4.77B | $6.21B | $5.41B | $3.34B | $1.66B |
| Net Income? | $5.28B | $18.99B | $16.17B | $2.20B | $15.91B | $13.96B | $14.50B | $13.47B | $6.50B | $5.58B |
| EPS? | $107.05 | $385.71 | $328.59 | $44.72 | $323.35 | $283.62 | $294.72 | $253.32 | $122.03 | $113.32 |
| Diluted EPS? | $107.05 | $385.71 | $328.59 | $44.72 | $316.19 | $271.93 | $272.61 | $253.32 | $122.03 | $104.74 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality